Evidence map›Paper›PMID 26917418›Full record

ArticleGenome medicine2016

Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.

Elizabeth Ernestina Godoy-Lozano, Juan Téllez-Sosa, Gilberto Sánchez-González, Hugo Sámano-Sánchez, Andrés Aguilar-Salgado, Aarón Salinas-Rodríguez, Bernardo Cortina-Ceballos, Héctor Vivanco-Cid, Karina Hernández-Flores, Jennifer M Pfaff and 7 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Lower Somatic Mutation Levels in theEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Elizabeth Ernestina Godoy-LozanoCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Juan Téllez-SosaCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Gilberto Sánchez-GonzálezCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Hugo Sámano-SánchezCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Andrés Aguilar-SalgadoCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Aarón Salinas-RodríguezCentro de Investigación en Evaluación y Encuestas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Bernardo Cortina-CeballosCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Héctor Vivanco-CidInstituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Veracruz, México.
Karina Hernández-FloresInstituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz, Veracruz, México.
Jennifer M PfaffIntegral Molecular Inc., Philadelphia, PA, USA.
Kristen M KahleIntegral Molecular Inc., Philadelphia, PA, USA.
Benjamin J DoranzIntegral Molecular Inc., Philadelphia, PA, USA.
Rosa Elena Gómez-BarretoCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Humberto Valdovinos-TorresCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Irma López-MartínezInstituto de Diagnóstico y Referencia Epidemiológicos, México, DF, México.
Mario H RodriguezCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
Jesús Martínez-BarnetcheCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México. jmbarnet@insp.mx.
Instituto Nacional de Salud Pública · MXIntegral Molecular (United States) · USUniversidad Veracruzana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study of human B cell response to dengue virus (DENV) infection is critical to understand serotype-specific protection and the cross-reactive sub-neutralizing response. Whereas the first is beneficial and thus represents the ultimate goal of vaccination, the latter has been implicated in the development of severe disease, which occurs in a small, albeit significant, fraction of secondary DENV infections. Both primary and secondary infections are associated with the production of poly-reactive and cross-reactive IgG antibodies.

methodsTo gain insight into the effect of DENV infection on the B cell repertoire, we used VH region high-throughput cDNA sequencing of the peripheral blood IgG B cell compartment of 19 individuals during the acute phase of infection. For 11 individuals, a second sample obtained 6 months later was analyzed for comparison. Probabilities of sequencing antibody secreting cells or memory B cells were estimated using second-order Monte Carlo simulation.

resultsWe found that in acute disease there is an increase in IgG B cell diversity and changes in the relative use of segments IGHV1-2, IGHV1-18, and IGHV1-69. Somewhat unexpectedly, an overall low proportion of somatic hypermutated antibody genes was observed during the acute phase plasmablasts, particularly in secondary infections and those cases with more severe disease.

conclusionsOur data are consistent with an innate-like antiviral recognition system mediated by B cells using defined germ-line coded B cell receptors, which could provide a rapid germinal center-independent antibody response during the early phase of infection. A model describing concurrent T-dependent and T-independent B cell responses in the context of DENV infection is proposed, which incorporates the selection of B cells using hypomutated IGHV segments and their potential role in poly/cross-reactivity. Its formal demonstration could lead to a definition of its potential implication in antibody-dependent enhancement, and may contribute to rational vaccine development efforts.

Indexed as

Somatic Hypermutation, ImmunoglobulinAcute DiseaseAdolescentAdultAmino Acid MotifsB-LymphocytesCluster AnalysisComplementarity Determining RegionsComputational BiologyDengueDengue VirusFemaleGene Expression ProfilingGerminal CenterHigh-Throughput Nucleotide SequencingHumansComplementarity Determining RegionsImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID26917418
PMCPMC4766701
OpenAlexW2281282442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.